long intergenic non-protein coding RNA 1852Genealiases: []
Q-omics provides the consensus-scored LINC01852 profile across patient tissues and cancer cell-line models. LINC01852 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01852 is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, LINC01852 RNA expression shows 17,611 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KICH, and UVM as cancer lineages where LINC01852 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01852 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01852 survival associations across molecular data types. LINC01852 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01852 RNA expression–survival associations across cancer types. High LINC01852 expression shows unfavorable associations in UVM, but favorable associations in KIRP, LUAD, KIRC, UCEC and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01852 RNA expression.
This table summarizes LINC01852 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01852. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01852 shows lower tumor expression in KICH, LUAD, LUSC, BLCA, BRCA and THCA. The KICH box plot shows higher LINC01852 RNA expression in normal versus tumor tissue (log2 FC = −2.033, t-test p < 0.001).
This table shows molecular features associated with LINC01852 in patient tissues and cancer cell lines. In patient samples, LINC01852 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
